Minimal Residual
Disease (MRD) – B-ALL
_
Overview Minimal Residual Disease (MRD) testing is a highly sensitive diagnostic tool used to detect small amounts of leukemia cells that remain in the body after treatment for B-cell Acute Lymphoblastic Leukemia (B-ALL). Even when a patient appears to be in remission under conventional methods, MRD testing identifies microscopic levels of disease, helping clinicians make informed treatment decisions.
Key Features of Our MRD Testing Service
_
  • High SensitivityWe utilize advanced techniques like Flow Cytometry and PCR-based assays to detect leukemia cells at levels as low as 1 in 10,000.
  • Fast Turnaround TimeResults are provided promptly to enable timely clinical decisions.
  • Accurate ResultsOur state-of-the-art laboratory ensures precise and reliable MRD measurements.
  • Expert InterpretationOur team of experienced hematopathologists interprets MRD results to guide your treatment journey.
Why MRD Testing is Essential for B-ALL Patients?
_

Early Detection

MRD testing detects tiny amounts of leukemia cells that may not be visible through traditional diagnostics like bone marrow morphology.

Prognostic Value

MRD results provide critical insights into treatment response and the likelihood of relapse.

Personalized Therapy

Identifying MRD positivity enables the tailoring of treatment plans to improve patient outcomes.

Monitoring Disease Progression

Continuous MRD testing helps track the effectiveness of treatment and identifies relapse at the earliest stage.
How It Works
_
The process begins with sample collection, where bone marrow or peripheral blood samples are carefully obtained. These samples then undergo advanced analysis using techniques such as Flow Cytometry or PCR to detect any remaining leukemia cells with high sensitivity. Finally, comprehensive reports are generated and shared with clinicians, providing detailed insights that facilitate informed treatment decisions.
Benefits of Choosing Us
_
  • Cutting-edge technology for MRD detection.
  • Personalized approach to leukemia management.
  • Supportive and dedicated laboratory services.
  • Trusted by leading hematologists and oncologists.
Who Should Undergo MRD Testing?
_
  • Patients undergoing treatment for B-ALL.
  • Individuals in remission to monitor minimal residual disease.
  • Patients before and after bone marrow transplantation.